Want to see ZTS full AI Analyst Report?
ZTS Stock Chart & Stats
$122.38
$1.04(0.64%)
At close: 4:00 PM EST
$122.38
$1.04(0.64%)
Day’s Range― - ―
52-Week Range$72.38 - $161.77
Previous CloseN/A
Volume625.10K
Average Volume (3M)9.42M
Market Cap
$30.13B
Enterprise Value$39.69B
Total Cash (Recent Filing)$1.94B
Total Debt (Recent Filing)$9.24B
Price to Earnings (P/E)11.9
Beta0.37
Next Earnings
Aug 06, 2026EPS Estimate
1.86Next Dividend Ex-DateN/A
Dividend Yield1.69%
Share Statistics
EPS (TTM)6.04
Shares Outstanding419,228,120
10 Day Avg. Volume7,355,948
30 Day Avg. Volume9,420,480
Financial Highlights & Ratios
PEG Ratio2.04
Price to Book (P/B)16.75
Price to Sales (P/S)5.89
P/FCF Ratio24.44
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue4.17
Enterprise Value/Gross Profit5.90
Enterprise Value/Ebitda9.85
Forecast
1Y Price Target
$104.75Price Target Upside-14.41% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)6.9
Revenue Forecast (FY)$9.76B
Bulls Say, Bears Say
Bulls Say
High And Expanding ProfitabilityZoetis’s sustained high gross (~71%) and net (~28%) margins, alongside multi-year revenue growth to $9.5B TTM, indicate durable product-level economics and pricing power. Strong margins support reinvestment in R&D, commercial expansion and shareholder returns, bolstering long-term competitiveness and return on invested capital.
Robust Free Cash Flow GenerationConsistent operating cash flow (~$2.7B TTM) and FCF (~$2.1B) demonstrate durable cash conversion and funding capacity for dividends, buybacks and M&A without relying on external financing. This supports capital allocation flexibility and resilience through industry cycles despite occasional conversion variability.
Pipeline And Strategic M&A ExpansionA sizeable pipeline (12 potential blockbusters, >$7B opportunity) and targeted deals like Neogen’s animal genomics broaden product and tech breadth. These moves strengthen long-term growth vectors in livestock genetics, diagnostics and specialty therapeutics, diversifying revenue and reinforcing competitive moats.
Bears Say
U.S. Companion-animal Demand WeaknessPronounced U.S. companion-animal declines (-11%) reflect lower clinic traffic and rising pet-owner price sensitivity. Given the large share of revenue from companion care, sustained softness or slower clinic visits could materially pressure topline growth and limit pricing levers over the medium term.
Competitive Pressure And Generics ErosionGeneric entrants and intensified promotions have eroded sales of former blockbusters, reducing durable revenue from legacy products. Persistent generic competition raises the burden on new launches to replace lost volumes and compresses pricing and margin sustainability in affected franchises.
Balance-sheet Volatility And Shrinking EquityWide swings in leverage and a decline in shareholders’ equity from ~$5.0B to ~$3.2B indicate balance-sheet volatility. Variable leverage reduces financial flexibility for large investments or downturns, and falling equity can constrain capital structure options and raise stakeholder scrutiny over long-term funding strategies.
Zoetis News
ZTS FAQ
What was Zoetis’s price range in the past 12 months?
Zoetis lowest stock price was $72.38 and its highest was $161.77 in the past 12 months.
What is Zoetis’s market cap?
Zoetis’s market cap is $30.13B.
When is Zoetis’s upcoming earnings report date?
Zoetis’s upcoming earnings report date is Aug 06, 2026 which is in 36 days.
How were Zoetis’s earnings last quarter?
Zoetis released its earnings results on May 07, 2026. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.604 by -$0.074.
Is Zoetis overvalued?
According to Wall Street analysts Zoetis’s price is currently Overvalued.
Does Zoetis pay dividends?
Zoetis pays a Quarterly dividend of $0.53 which represents an annual dividend yield of 1.69%. See more information on Zoetis dividends here
What is Zoetis’s EPS estimate?
Zoetis’s EPS estimate is 1.86.
How many shares outstanding does Zoetis have?
Zoetis has 419,228,120 shares outstanding.
What happened to Zoetis’s price movement after its last earnings report?
Zoetis reported an EPS of $1.53 in its last earnings report, missing expectations of $1.604. Following the earnings report the stock price went down -21.498%.
Which hedge fund is a major shareholder of Zoetis?
Currently, no hedge funds are holding shares in ZTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zoetis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$104.75 (-14.41% Downside)
$104.75 (-14.41% Downside)
Blogger Sentiment
Bullish
ZTS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 508.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $886.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.20%
12-Months-Change
Fundamentals
Return on Equity
62.41%
Trailing 12-Months
Asset Growth
7.49%
Trailing 12-Months
Company Description
Zoetis
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
ZTS Company Deck
ZTS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Mixed quarter: strong execution in livestock, international markets, diagnostics, margin improvement ex-FX, EPS and adjusted net income growth, and a solid pipeline/M&A strategy contrast with pronounced weakness in U.S. companion animal (dermatology, parasiticides and OA pain), channel destocking, generic incursions on select products, fiscal alignment timing and FX headwinds. Management has taken decisive cost and commercial actions and provided positive full-year guidance, but near-term risks and competitive intensity leave the recovery path uncertain.View all ZTS earnings summariesZTS Revenue Breakdown
20.69% Vaccines
24.73% Parasiticides
18.53% Dermatology
10.94% Anti-infectives
8.87% Pain and sedation
7.36% Other pharmaceuticals
4.58% Animal health diagnostics
2.78% Other non-pharmaceuticals
0.29% Medicated feed additives
1.23% Contract manufacturing & human health
ZTS Stock 12 Month Forecast
Average Price Target
$104.75
▼(-14.41% Downside)
Technical Analysis
Ownership Overview
0.08% Insiders
22.43% Mutual Funds
25.40% Other Institutional Investors
19.74% Public Companies and Individual Investors